文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[225Ac]Ac-PSMA治疗[177Lu]Lu-PSMA难治性转移性去势抵抗性前列腺癌患者的临床经验

Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-08-24

该回顾性分析纳入23例对[177Lu]Lu-PSMA治疗难治的mCRPC患者,在2018年12月至2022年10月期间接受[225Ac]Ac-PSMA治疗。首周期后50%患者(9/18)按PSMA PET进展标准出现疾病进展,疾病控制率为50%;中位无进展生存期3.1个月,中位总生存期7.7个月。1例发生3级血液学毒性,另1例发生3级肾毒性;作者结论认为[225Ac]Ac-PSMA治疗安全并在晚期mCRPC中显示潜力。

要点

  • 23例[177Lu]Lu-PSMA难治性mCRPC患者接受[225Ac]Ac-PSMA,中位无进展生存期3.1个月。
  • 首周期后PSMA PET评估疾病控制率为50%(9/18),中位总生存期7.7个月。
  • 1例3级血液学毒性、1例3级肾毒性;腮腺SUVmax下降33%。

核心结论

  • 作者观察到[225Ac]Ac-PSMA治疗是安全的,即使在所有其他治疗选择均已完成的晚期mCRPC病例中也显示出潜力。

研究设计与样本

  • 回顾性分析2018年12月至2022年10月期间接受[225Ac]Ac-PSMA治疗的23例mCRPC患者(平均年龄70.3±8.8岁),这些患者对[177Lu]Lu-PSMA治疗(2-9周期)难治。
  • 安全性按不良事件通用术语标准5.0版评估;疗效在[225Ac]Ac-PSMA首周期后采用PSMA PET进展标准和PCWG2标准的PSA反应评估。

主要发现

  • 全部患者接受雄激素剥夺治疗,22例(96%)接受化疗,19例(83%)接受第二代抗雄激素治疗。
  • 1例接受4周期、2例接受3周期、8例接受2周期、12例接受1周期[225Ac]Ac-PSMA;周期中位间隔13周(范围8-28周);每周期平均给药活度7.6 MBq(范围6.2-10.0 MBq)。
  • 最佳PSA反应见于5例(26%)患者,至少有一定程度PSA下降见于11例(58%;n=19)。
  • 首周期后(n=18)50%患者(n=9)按PSMA PET进展标准显示疾病进展,疾病控制率为50%。
  • 中位无进展生存期3.1个月,中位总生存期7.7个月;1例发生3级血液学毒性,另1例发生3级肾毒性;腮腺SUVmax下降33%,尽管全部患者在治疗前主诉口干。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [225Ac]Ac-PSMA between December 2018 and October 2022. Methods: We evaluated the treatment results of 23 patients (mean age, 70.3 ± 8.8 y) with mCRPC who were refractory to treatment with [177Lu]Lu-PSMA (2-9 cycles). The safety profile was assessed according to Common Technology Criteria for Adverse Events version 5.0. Treatment efficacy was assessed using prostate-specific membrane antigen PET progression criteria and prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 2 criteria after the first cycle of [225Ac]Ac-PSMA treatment. Results: All patients received androgen-deprivation therapy, whereas 22 (96%) and 19 (83%) patients received chemotherapy and second-generation antiandrogen therapy, respectively. One patient received 4 cycles, 2 received 3 cycles, 8 received 2 cycles, and 12 received 1 cycle of [225Ac]Ac-PSMA. The median interval between cycles was 13 wk (range, 8-28 wk). [225Ac]Ac-PSMA was administered with a mean activity of 7.6 MBq (range, 6.2-10.0 MBq) in each cycle. Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [225Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; n = 19). Treatment response was assessed in patients who underwent [68Ga]Ga-PSMA PET/CT imaging. After the first cycle of treatment (n = 18), 50% of patients (n = 9) showed disease progression according to prostate-specific membrane antigen PET progression criteria, and the disease control rate was calculated to be 50%. Median progression-free survival was 3.1 mo, and median overall survival was 7.7 mo. Grade 3 hematologic toxicity occurred in 1 patient, and grade 3 nephrotoxicity was observed in another patient. Parotid SUVmax decreased by 33%, although all patients complained of dry mouth before treatment. Conclusion: We observed that [225Ac]Ac-PSMA therapy was safe and showed potential even in cases with advanced-stage mCRPC in which all other treatment options were completed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Alan-Selcuk N, Beydagi G, Demirci E, et al. Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2023. PMID: 37620050. doi:10.2967/jnumed.123.265546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。